ReviewCancer reports (Hoboken, N.J.)2025
Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and Development.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and Development.Cancer reports (Hoboken, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is the most frequent primary bone malignancy, affecting mainly children, adolescents, and young adults. For the past 40 years, improvements in the survival of patients with osteosarcoma have been minimal, primarily as a consequence of the lack of systemic therapy options beyond traditional cytotoxic agents. In particular, management of metastatic and recurrent disease continues to be a significant clinical challenge. RECENT
findingsMouse models of osteosarcoma serve as a valuable tool to study disease biology, metastasis, and response to novel treatments. In recent years, mouse models have been employed to evaluate the efficacy of several innovative drugs, including nanoparticle formulations that can target drug delivery to osteosarcoma tumor cells and diminish off-target effects. In addition, significant preclinical advancements in immune checkpoint inhibitors and immunotherapies for osteosarcoma have been made with the aid of mouse models.
conclusionThis review provides insight into the advantages and shortcomings of the numerous osteosarcoma mouse models described in the literature, including transgenic, orthotopic, and heterotopic models as well as patient-derived xenografts. We highlight how these models are currently being used to support preclinical studies focused on the development of novel therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.